Tickets are available – and registration will be open right up until the day of the event – for the 2024 Protein Science in ...

- Congruence's insights into the biology and pharmacology of MC4R deficiency and its proprietary drug discovery engine, Revenirtm, identified MC4R corrector small molecules with the potential to treat ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting ...

Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...

Since 2017, an advanced R&D system which covers target discovery, early discovery ... an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors” as a poster presentation at the ...

Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monotherapy in a ...

Alexander Fleming’s 1928 discovery of a mold with antibacterial properties was only the first serendipitous event on the long ...

About NX-5948: NX-5948 is an investigational, orally bioavailable degrader of BTK that is currently being evaluated in a ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.